Yahoo
NasdaqGS - Delayed Quote USD

Mesa Laboratories, Inc. (MLAB)

128.25 +8.95 (+7.50%)
At close: November 6 at 4:00:01 PM EST
128.25 -0.35 (-0.27%)
After hours: November 6 at 4:00:15 PM EST
Trade MLAB on Coinbase
MLAB Q2 2027 earnings call
Today at 4:30 PM EST
Chart Range Bar
Loading chart for MLAB
Chart does not reflect overnight price.
  • Previous Close 119.30
  • Open 120.50
  • Bid 89.63 x 200
  • Ask 153.67 x 200
  • Day's Range 120.50 - 128.60
  • 52 Week Range 69.51 - 144.35
  • Volume 109,672
  • Avg. Volume 128,131
  • Market Cap (intraday) 717.67M
  • Beta (5Y Monthly) 1.08
  • PE Ratio (TTM) 150.88
  • EPS (TTM) 0.85
  • Earnings Date Nov 9, 2026
  • Forward Dividend & Yield 0.64 (0.50%)
  • 1y Target Est 125.00
  • Moby Rating Neutral

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

www.mesalabs.com

717

Full Time Employees

March 31

Fiscal Year Ends

Technology

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MLAB
64.11%
S&P 500 (^GSPC)
7.76%

1-Year Return

MLAB
72.41%
S&P 500 (^GSPC)
9.77%

3-Year Return

MLAB
42.19%
S&P 500 (^GSPC)
68.96%

5-Year Return

MLAB
59.23%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 60.14M
Earnings 2.83M
Profit Margin 4.71%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
20M
40M
60M
-6.0%
-4.0%
-2.0%
0.0%
2.0%
4.0%

Analyst Insights

View More

Analyst Price Targets

125.00 Low
125.00 Average
128.25 Current
125.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/14/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Equal-Weight
Price Action Raises
Price Target 94 -> 110

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.92%

  • Return on Assets (ttm)

    3.29%

  • Return on Equity (ttm)

    2.66%

  • Revenue (ttm)

    249.72M

  • Net Income Avi to Common (ttm)

    4.8M

  • Diluted EPS (ttm)

    0.85

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    32.24M

  • Total Debt/Equity (mrq)

    85.48%

  • Levered Free Cash Flow (ttm)

    53.38M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: